Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that all members of its board of directors and management have signed lock-up agreements for their shares and/or other securities in the company until and including December 31, 2026.
All members of the company’s board of directors and management have entered into agreement not to sell their shares and/or other securities in the company in any way, also known as lock-up agreements, during the period until and including December 31, 2026. The lock-up prevents transfer or disposal of shares and/or other securities in the company, with certain exceptions.
“The decision by all members of the Board of Directors and management to enter into lock-up agreements is a clear expression of our shared long-term commitment to Cereno Scientific. The company is at an important stage, with a strengthened position, significant clinical and regulatory progress, and ongoing business development and partnering activities. Through these commitments, we want to demonstrate our confidence in the company’s strategy and our focus on creating long-term value for shareholder,” said Jeppe Øvlesen, Chairperson of the Board of Directors, Cereno Scientific.
“We have strong momentum at Cereno Scientific, with important clinical and regulatory priorities ahead of us and intensified partnering activities. The decision by all members of the Board of Directors and management to enter into lock-up agreements demonstrates our strong confidence in the company’s future development and our shared ambition to create value for shareholders. We fully support the strategy and remain focused on leveraging the opportunities enabled by the company’s strengthened position,” said Sten R. Sörensen, CEO and board member of Cereno Scientific.